Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

Sorafenib and regorafenib administration is among the preferential approaches to treat hepatocellular carcinoma (HCC), but does not provide satisfactory benefits. Intensive crosstalk occurring between cancer cells and other multiple non-cancerous cell subsets present in the surrounding microenvironm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Dis
Autori principali: Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669886/
https://ncbi.nlm.nih.gov/pubmed/33199679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03180-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi